MRS2 and endometrial cancer: By contrast, a 3-marker panel of plasma proteins combining APOD, PSMA7 and HPT predicted endometrial cancer with an AUC of 0.87 (0.81–0.93), sensitivity of 75%, and specificity of 84%.